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Background and Purpose  New diagnostic criteria for pediatric autoimmune encephalitis 
(AIE) have been introduced recently. A substantial proportion of cases of pediatric AIE are 
diagnosed as seronegative based on these criteria, and so the clinical characteristics of this 
group remain to be investigated.
Methods  This study included 46 pediatric patients younger than 18 years with suspected 
AIE. Clinical features, laboratory or radiological findings, and treatment outcomes were 
compared between seronegative and seropositive patients.
Results  Nine (19.6%) of the 46 patients were diagnosed as seropositive AIE. All of the pa-
tients with seropositive AIE had anti-N-methyl-D-aspartate receptor antibodies. Commonly 
identified neuropsychiatric symptoms were altered mental status, cognitive dysfunction, sei-
zure, speech dysfunction, and psychotic disorder in both the seronegative and seropositive 
groups. Immunotherapy produced favorable treatment outcomes in both the seropositive 
(n=7, 77.8%) and seronegative (n=35, 94.6%) AIE patients. Treatment outcomes for first-line 
immunotherapy were better in seronegative AIE than seropositive AIE patients (p=0.003), and 
hence a smaller proportion of seronegative patients required second-line treatment (p=0.015). 
Conclusions  Pediatric seronegative AIE patients showed clinical presentations similar to 
those of seropositive AIE patients, with favorable treatment outcomes after immunotherapy.
Key Words   encephalitis, autoimmune encephalitis, seronegative encephalitis.
Clinical Features and Treatment Outcomes of Seronegative 
Pediatric Autoimmune Encephalitis
INTRODUCTION
Autoimmune encephalitis (AIE) is a neuroinflammatory disorder characterized by diverse 
neuropsychiatric symptoms and autoantibodies targeting neuronal antigens.1-4 After the ini-
tial discovery of antibodies against the N-methyl-D-aspartate receptor (NMDAR) in 2007,5 
several more antibodies against neuronal cell surface or synaptic antigens, intracellular an-
tigens, or onconeuronal antigens have been identified.6 However, most AIE cases remain 
seronegative, with precise mechanisms still being investigated.7-9
Differentiating pediatric from adult cohorts has recently been emphasized when identi-
fying clinical features and treatment outcomes. Therefore, a diagnostic approach to AIE has 
been proposed specifically for pediatric cohorts.10,11 Clinical presentations of AIE in pedi-
atric patients differ in several ways from those in adult-onset AIE patients: 1) seropositive 
patients present with a narrower range of autoantibodies targeting mostly anti-NMDAR, 
anti-GABA-A receptor, and anti-GAD65; 2) most patients present as clinically ill-defined 
seronegative syndromes; and 3) numerous differential diagnoses are present according to 
the developmental status.12-14 However, few studies have exclusively investigated pediatric 
cohorts, and most of the studies conducted in pediatric patients have focused on patients 
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who were diagnosed as anti-NMDAR encephalitis.15,16 More 
data are therefore needed on seronegative AIE in children.
This study identified cases of seronegative AIE and com-
pared their clinical features, disease severity, and treatment 
outcomes with those for seropositive AIE. The findings of this 
study will provide an outline for clinicians to use when diag-
nosing and maintaining treatment in pediatric AIE patients.
METHODS
Patient selection
We selected patients who were initially diagnosed with sus-
pected encephalitis, tested for an autoantibody panel of AIE, 
and confirmed with AIE at a single center, Severance Hospi-
tal, from June 2016 to June 2020. We only included pediatric 
patients younger than 18 years with suspected AIE who were 
followed up for at least 1 year. Seropositive and seronegative 
AIE were clinically diagnosed based on the recent report of 
Cellucci et al.11 Both seronegative-possible and seronegative-
probable AIE were defined as seronegative AIE when alter-
native diagnoses were excluded. We excluded patients who 
were diagnosed with any of the following conditions: 1) in-
fectious encephalitis with laboratory evidence of central ner-
vous system infection; 2) various neuroinflammatory disor-
ders, such as acute disseminated encephalomyelitis or febrile 
illness-related epilepsy syndrome; 3) primary psychiatric dis-
orders; or 4) previous primary neurological disorder that might 
have been the cause of the clinical presentation. This study 
was approved by the institutional review boards of Sever-
ance Hospital (4-2020-0687).
Clinical evaluation
Demographic characteristics of the patients were collected 
through a review of electronic medical records. Clinical ev-
idence of neuropsychiatric dysfunction included 1) altered 
mental status, 2) focal neurological deficit, 3) cognitive dys-
function, 4) acute developmental regression, 5) movement 
disorder, 6) seizure, 7) speech dysfunction, 8) psychotic symp-
toms, 9) sleep disorder, or 10) autonomic dysfunction. Fur-
thermore, information was obtained on the presence of pro-
dromal symptoms, a vaccination history, age at onset, sex, 
initial disease severity, and treatment outcomes. Disease se-
verity and treatment outcomes were determined by obtain-
ing modified Rankin Scale (mRS) scores at the onset of symp-
toms, before and after each immunomodulatory treatment, 
and at the final end point (1 year after clinical onset).17-19 The 
presence of tumor (e.g., ovarian teratoma) was investigated 
using abdominal pelvic computed tomography (CT) or so-
nography. The duration of stay in the intensive care unit was 
also reviewed. Electroencephalographic findings were fur-
ther reviewed for epileptiform discharges and encephalopath-
ic background, such as diffuse or focal slowing.
Laboratory test results were also collected. The findings of 
blood tests, urine analysis, and initial cerebrospinal fluid (CSF) 
analysis with CSF culture and polymerase chain reaction anal-
ysis for infectious encephalitis (HSV-1, HSV-2, EBV, CMV, 
VZV, enterovirus, and panel for bacterial encephalitis) were 
obtained in order to identify and exclude other possible eti-
ologies of encephalopathy. CSF inflammatory change was de-
fined as leukocytosis >5 cells/mm3, elevated protein levels, 
and/or oligoclonal banding.
Radiological findings were acquired, and a diagnosis was 
made based on magnetic resonance imaging (MRI) of the 
brain. Features of encephalitis according to brain MRI (e.g., 
increased T2/FLAIR signal intensity in the mesial temporal 
lobes) were identified as paraclinical evidence of neuroinflam-
mation. In some patients with normal brain MRI findings, 
positron-emission tomography/CT (PET-CT) of the brain 
was conducted to identify brain dysfunction and neuroin-
flammation.
Immunomodulatory therapy
Since the early initiation of primary immunotherapy enhanc-
es treatment outcomes in AIE, our patients received immuno-
modulatory agents as soon as AIE was diagnosed.20 For first-
line immunotherapy, separate or combined use of high-dose 
dexamethasone (0.6–0.8 mg/kg/day), pulsed intravenous 
methylprednisolone (20–30 mg/kg/day for 3–5 days), intra-
venous immunoglobulin (2 g/kg over 2–5 days), or therapeu-
tic plasma exchange (5–10 exchanges every other day) was 
initiated in our center. If the symptoms were not relieved with-
in 2 weeks, second-line immunotherapy was initiated with 
rituximab (375 mg/m2 weekly for 4 weeks) or cyclophospha-
mide (750 mg/m2 monthly). When the patients did not im-
prove, tocilizumab (4–8 mg/kg monthly) was tried as third-line 
immunotherapy. Finally, for those with prolonged symptoms 
or frequent relapses, chronic immunosuppression with month-
ly administration of methylprednisolone or immunoglobulins, 
oral prednisone (1 mg/kg/day), mycophenolate mofetil, or 
azathioprine was considered as maintenance treatment.
Antibody screening
Patient sera and CSF specimens were initially collected and 
sent to a laboratory at Seoul National University for the de-
tection of autoantibodies.21,22 A cell-based indirect immuno-
fluorescence test was used to detect autoantibodies to anti-
NMDAR, anti-LGI1, anti-CASPR2, anti-AMPA1 receptor, 
anti-AMPA2 receptor, and anti-GABA-B receptor. In brief, 
diluted patient sera and CSF (1:10) were reacted with HEK293 
cells transfected with plasmids containing human target gene 
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sequences (Euroimmun, Lübeck, Germany), and fluorescein-
isothiocyanate-labeled antihuman immunoglobulin G was 
used as the secondary antibody. A positive reaction was de-
fined as the presence of cytoplasmic immunofluorescence.
Statistical analysis
The clinical features of patients according to serological sta-
tus were compared in order to identify the associated factors. 
Numerical and categorical data were compared between two 
groups using Student’s t-test, Mann-Whitney test, chi-square 
test, or Fisher’s exact test, as appropriate. A linear mixed model 
was used to identify the factors associated with treatment 
outcomes in seronegative AIE. Treatment outcomes of sero-
positive AIE patients and seronegative AIE patients after the 
second-line or maintenance treatment were not included in 
the model due to the small cohort. 
The Statistical Package for the Social Sciences (version 23.0, 
IBM Corp., Armonk, NY, USA) was used for all statistical 
analyses, and p values <0.05 were considered statistically sig-
nificant. Data are presented as number and percentage, mean± 




This study reviewed 92 patients who were diagnosed with 
suspected encephalitis. Upon applying the diagnostic crite-
ria recently proposed by Cellucci et al.11 and excluding pa-
tients with alternative diagnoses, 46 patients were finally 
diagnosed as AIE. Nine (19.6%) patients tested positive for 
antibodies, all of which were anti-NMDAR encephalitis. The 
remaining 37 (80.4%) seronegative AIE patients comprised 
10 (21.7%) diagnosed as possible AIE and 27 (58.7%) diag-
nosed as seronegative-probable AIE.
The 46 AIE patients included 22 (47.8%) males. The age at 
disease onset was 9.6±4.6 years. Twenty-nine patients were 
evaluated for a possible tumor, and two (6.9%) seropositive 
AIE patients were diagnosed with ovarian teratoma, which 
was treated by surgical removal. Prodromal symptoms and 
a vaccination history before the clinical onset of AIE were 
noted in 36 (78.3%) patients, with the most common symp-
tom being fever (n=30, 65.2%). The most frequent neuropsy-
chiatric symptom at the initial admission was seizure (n=28, 
60.1%). Inflammatory changes in the CSF were diagnosed in 
26 (56.5%) patients, and abnormal MRI findings suggestive 
of AIE were noted in 21 (45.7%) patients. Brain biopsy was 
not performed in our cohort. Electroencephalographic sig-
nals exhibited slow and disorganized backgrounds in all of 
the patients, and focal epileptic discharges or slowing was di-
agnosed in 20 (43.5%) patients.
The most common clinical feature of neuropsychiatric dys-
function in our cohort during the follow-up period was psy-
chiatric symptoms (n=40, 85.1%), followed by speech dysfunc-
tion (n=38, 82.6%), seizure (n=37, 80.4%), altered mental 
status (n=36, 78.3%), cognitive dysfunction (n=36, 78.3%), 
movement disorder (n=28, 60.9%), acute developmental re-
gression (n=27, 58.7%), sleep disorder (n=22, 47.8%), auto-
nomic dysfunction (n=17, 37.0%), and focal neurological def-
icit (n=4, 8.7%). Forty-two (91.3%) patients had at least four 
neuropsychiatric features.
Clinical characteristics and treatment outcomes
The sex ratio did not differ significantly with the serological 
status, with 3 of 9 (33.3%) male patients diagnosed as sero-
positive AIE and 19 of 37 (51.4%) male patients diagnosed 
as seronegative AIE (p=0.464). The age at disease onset was 
11.4±5.6 years in seropositive AIE patients and 9.2±4.3 years 
in seronegative AIE patients (p=0.196). Tumor (ovarian ter-
atoma) was diagnosed in only two of the nine (22.2%) patients 
with seropositive AIE (anti-NMDAR encephalitis) (p=0.089). 
Prodromal symptoms or a vaccination history were initially 
present in 5 of the 9 (55.6%) seropositive AIE patients and 
31 of the 37 (83.8%) seronegative AIE patients (p=0.087). Pa-
tients diagnosed with seropositive AIE tended to present with 
more-diverse clinical features of neuropsychiatric dysfunc-
tion compared with seronegative AIE patients (p=0.038; mRS 
score=7.4±1.3 vs. 5.9±2.1). Neurological dysfunction such as 
seizure or speech dysfunction was more common in seroposi-
tive patients during the overall follow-up period, while psy-
chological dysfunction was more common in seronegative 
patients. However, both seropositive and seronegative AIE 
patients more commonly presented with neurological symp-
toms than psychotics disorders at admission (Table 1).
Inflammatory changes in CSF were noted in 6 of the 9 (66.7%) 
patients with seropositive AIE and 20 of the 37 (54.1%) patients 
with seronegative AIE (p=0.711), while encephalitic features 
in radiological findings were detected in 2 (22.2%) and 19 
(51.4%) patients, respectively (p=0.151). PET-CT was conduct-
ed in only four (10.8%) seronegative AIE patients, and they 
exhibited with hyper- or hypometabolism of the brain, sug-
gestive of an encephalitic feature (Table 1). 
Since the initial disease severity as assessed using mRS scores 
showed severe disability in both seropositive (median=5, IQR= 
0) and seronegative (median=4, IQR=2) encephalitis (p=0.086), 
first-line treatment was initiated in all patients regardless of 
their serological status. However, outcomes after the initiation 
of first-line treatment were better in seronegative AIE patients 
(median=1, IQR=2) than in seropositive AIE patients (me-
dian=4, IQR=2) (p=0.003). Therefore, second-line treatment 
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(p=0.015) was applied more frequently in seropositive AIE 
(5/9, 55.6%). Maintenance treatment (p=0.092) was also ap-
plied more frequently in seropositive AIE (5/9, 55.6%), al-
though the difference was not statistically significant. Only 
one patient diagnosed as seropositive AIE received third-line 
treatment (p=0.196). Furthermore, although not statistically 
significant, disease relapse was more frequent in seronegative 
AIE (13/37, 35.1%) than in seropositive AIE (2/9, 22.2%) (p= 
0.696), but was not related to grave disease severity. Final treat-
ment outcomes after 1 year from disease onset showed the 
same mild severity in seropositive (median=1, IQR=2) and 
seronegative (median=1, IQR=2) groups (p=0.703) (Table 2).
Clinical features associated with treatment 
outcomes of seronegative AIE
First-line treatment was initiated in all 37 patients diagnosed 
as seronegative AIE. Second-line (n=5, 13.5%) and mainte-
nance (n=8, 21.6%) treatments were considered only in those 
with poor treatment outcomes after the first-line treatment or 
with disease relapse. One year after disease onset, 23 (62.2%) 
patients achieved an mRS score of 0 or 1, thereby presenting 
with almost no significant disabilities. Furthermore, only two 
(5.4%) patients presented with an mRS score ≥3 (moderate-
to-severe disability), indicating good treatment outcomes in 
seronegative AIE.
To exclude confounding factors, the clinical features asso-
ciated with favorable treatment outcomes were further ana-
lyzed using a linear mixed model. This analysis revealed that 
the disease severity of seronegative AIE improved over time 
(p<0.001), and that the mRS score after first-line treatment 
was the only factor associated with treatment outcome (p= 
0.006) (Table 3).
DISCUSSION
This study found that clinical presentations of pediatric AIE 
patients did not vary markedly with the serological status, and 
that both seronegative and seropositive AIE patients showed 
favorable treatment outcomes after applying the recently pro-
posed pediatric diagnostic criteria.11 This demonstrates the 







Male 19 (51.4) 3 (33.3) -
Female 18 (48.6) 6 (66.7) -
Age at onset, years 9.2±4.3 11.4±5.6 0.196
Tumor 0 2 (22.2) 0.089
Prodromal symptoms 31 (83.8) 5 (55.6) 0.087
Fever 27 (73.0) 3 (33.3) -
Headache 10 (27.0) 3 (33.3) -
Gastrointestinal symptom 10 (27.0) 3 (33.3) -
Respiratory symptom 7 (18.9) 0 -
Vaccination history 1 (2.7) 0 -
Neuropsychiatric features,  
  mRS score
5.9±2.1 7.4±1.3 0.038*
Altered mental status 29 (78.4) 7 (77.8) >0.999
Focal neurological deficit 2 (5.4) 2 (22.2) 0.167
Cognitive dysfunction 29 (78.4) 7 (77.8) >0.999
Acute developmental  
  regression 
20 (54.1) 7 (77.8) 0.270
Movement disorder 20 (54.1) 8 (88.9) 0.069
Seizure 28 (75.7) 9 (100.0) 0.171
Speech dysfunction 29 (78.4) 9 (100.0) 0.324
Psychotic disorder 32 (86.5) 8 (88.9) >0.999
Sleep disorder 16 (43.2) 6 (66.7) 0.276
Autonomic dysfunction 13 (35.1) 4 (44.4) 0.707
CSF inflammation 20 (54.1) 6 (66.7) 0.711
MRI abnormality 19 (51.4) 2 (22.2) 0.151
PET-CT abnormality 4 (10.8) 0 -
ICU stay 7 (18.9) 4 (44.4) -
Data are n (%) or mean±standard deviation values. 
*p<0.05.
AIE: autoimmune encephalitis, CSF: cerebrospinal fluid, ICU: intensive 
care unit, MRI: magnetic resonance imaging, mRS: modified Rankin 
Scale, PET-CT: positron-emission tomography/computed tomography.







Initial mRS score 4 [2] 5 [0] 0.086
mRS score after first-line  
  treatment 
1 [2] 4 [2] 0.003*
Final mRS score 1 [2] 1 [2] 0.703
First-line treatment 37 (100.0) 9 (100.0) -
Second-line treatment 5 (13.5) 5 (55.6) 0.015*
Third-line treatment 0 1 (11.1) 0.196
Maintenance treatment 8 (21.6) 5 (55.6) 0.092
Relapse 13 (35.1) 2 (22.2) 0.696
Data are median [interquartile range] or n (%) values. First-line treat-
ment: high-dose dexamethasone (0.6–0.8 mg/kg/day), pulsed intrave-
nous methylprednisolone (20–30 mg/kg/day for 3–5 days), intrave-
nous immunoglobulin (2 g/kg over 2–5 days), or therapeutic plasma 
exchange (5–10 exchanges every other day). Second-line treatment: 
rituximab (375 mg/m2 weekly for 4 weeks) or cyclophosphamide (750 
mg/m2 monthly). Third-line treatment: tocilizumab (4–8 mg/kg month-
ly). Maintenance treatment: monthly administration of methylpred-
nisolone or immunoglobulins, oral prednisone (1 mg/kg/day), myco-
phenolate mofetil, or azathioprine.
*p<0.05.
AIE: autoimmune encephalitis, mRS: modified Rankin Scale.
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validity of recent pediatric diagnostic criteria that are distinct 
from those for adult cohorts, and indicates that, despite a neg-
ative serological status, the autoimmune pathophysiology of 
seronegative AIE is similar to that of seropositive AIE.
While the clinical features and treatment outcomes of our 
pediatric AIE cohort mostly resembled those of adult-onset 
AIE, their initial presentations showed more neurological 
signs, such as seizure, altered mental status, and speech dys-
function, which contrast with higher prevalence rates of psy-
chotic disorders in adult-onset AIE reported previously.11,23,24 
However, psychotic symptoms or sleep disorder were also fre-
quently detected during the disease course, with more than 
90% of patients presenting with at least four neuropsychiatric 
features. Furthermore, autonomic dysfunction such as uri-
nary retention, tachycardia, bradycardia, or blood pressure 
fluctuation was common in both the anti-NMDAR-encepha-
litis-seropositive and anti-NMDAR-encephalitis-seronegative 
groups, which indicates the significance of the early suspicion 
and detection of clinical presentations in diagnosing AIE.
Childhood-onset seropositive AIE cases mostly comprise 
anti-NMDAR encephalitis, followed by anti-GABA-A-recep-
tor encephalitis or anti-GAD65 encephalitis.12 Anti-NMDAR 
encephalitis is the most common form of antibody-mediated 
encephalitis in pediatric cohorts, and is a prototypic AIE with 
an established clinical syndrome of neuropsychiatric dysfunc-
tion with favorable treatment outcomes in more than 80% 
of patients.25,26 Tumor (ovarian teratoma) association and fe-
male predominance characterize this patient group, despite 
the equal sex ratio, with a rare association with tumors in 
pediatric patients younger than 10 years.12,27 Consistent with 
this, nine of our patients diagnosed as seropositive AIE were 
all confirmed with anti-NMDAR encephalitis. These patients 
initially presented with a polysymptomatic clinical syndrome 
with grave disease severity, although seven (77.8%) of them 
showed favorable treatment outcomes after 1 year. Further-
more, two of four female patients who were older than 10 
years were diagnosed with ovarian teratoma, which was im-
mediately removed.
Gastaldi and colleagues28,29 reported that seronegative AIE 
presents with clinical phenotypes and relapse occurred sim-
ilarly to seropositive AIE, with more than 60% of adult pa-
tients showing favorable treatment responses. Hacohen et al.14 
also reported that clinical features (seizure predominance) 
and treatment outcomes of pediatric seronegative and sero-
positive AIE patients were similar at presentation. However, 
those previous studies did not apply objective diagnostic cri-
teria, and identified patients using a blinded clinical review 
panel. In the present study we were able to successfully iden-
tify patients with AIE by applying a new diagnostic approach 
proposed by experts. The seronegative patients in our pedi-
atric cohort showed similar clinical presentations with fa-
vorable treatment outcomes as those of the seropositive AIE 
patients, suggesting that this new diagnostic approach can 
effectively identify AIE patients regardless of their serum an-
tibody status.
The detection of autoantibodies for diagnosing AIE is not 
perfect for several reasons: 1) false negatives due to method-
ological problems and low titers, 2) phase lag relative to clini-
cal features, 3) possibility of unknown antibodies, and 4) un-
known mechanisms not associated with antibody-mediated 
immunity.14 Previous studies have found that considerable 
proportions of patients tested for AIE autoantibodies are se-
ronegative with unknown etiologies.14,28 Among our pediat-






Sex 0.017 0.226 0.941
Diagnosis -0.091 0.384 0.815
Prodromal symptoms 0.183 0.236 0.448
CSF inflammation 0.201 0.351 0.572
Altered mental status -0.080 0.235 0.737
Focal neurological deficit 0.315 0.419 0.461
Cognitive dysfunction -0.115 0.272 0.677
Acute developmental regression -0.142 0.217 0.519
Movement disorder 0.018 0.167 0.915
Psychotic disorder 0.336 0.347 0.345
Seizure -0.148 0.364 0.689
Speech dysfunction -0.142 0.256 0.585
Sleep disorder 0.031 0.199 0.878
Autonomic dysfunction -0.407 0.235 0.097
MRI abnormality -0.048 0.208 0.821
Second-line treatment -0.085 0.500 0.866
Maintenance treatment 0.605 0.415 0.161
Relapse -0.121 0.318 0.708
ICU stay 0.166 0.421 0.698
Initial mRS score 0.323
2 -0.801 0.421 -
3 -0.513 0.402 -
4 -0.395 0.338 -
mRS score after first-line treatment 0.006*
0 -2.563 0.915 -
1 -2.224 0.780 -
2 -1.277 0.737 -
3 -0.925 0.510 -
4 -0.448 0.614 -
Time <0.001*
*p<0.05.
AIE: autoimmune encephalitis, CSF: cerebrospinal fluid, ICU: intensive 
care unit, MRI: magnetic resonance imaging, mRS: modified Rankin 
Scale.
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ric AIE cohort, about only 20% of patients were diagnosed 
with autoantibodies against neuronal antigens, with 80% of 
patients diagnosed as seronegative AIE. This indicates the im-
portance of performing a precise analysis that compares se-
ronegative and seropositive AIE.
The early initiation of primary immunosuppressive strate-
gies, such as corticosteroids, intravenous immunoglobulin, 
or therapeutic plasma exchange, is usually associated with fa-
vorable treatment outcomes.30 We found that the disease se-
verity upon admission was not significantly associated with 
treatment outcomes, although mild disease severity after pri-
mary immunotherapy was significantly associated with an 
overall favorable outcome. Other clinical features were also 
investigated, and they were found to have no significant as-
sociations with treatment outcomes. Moreover, as in previ-
ous studies, disease severity was milder on relapse, suggesting 
that the presence of relapse was not related to an unfavorable 
treatment outcome.31,32 Therefore, the early initiation of pri-
mary immunotherapy and the precise identification of dis-
ease severity may be significant.
Several observational studies have demonstrated that ap-
propriate initiation of second-line immunotherapy results in 
better functional outcomes and lower relapse rates.27,33 Main-
tenance therapy is also recommended in a specific population 
of patients in order to improve functional outcomes and en-
sure long-term complete remission.30 Among 16 patients in 
our cohort with moderate-to-severe disease severity (mRS 
score ≥3) after primary immunomodulatory therapies, 13 
(81.3%) received either second-line or maintenance immu-
notherapy, which led to better functional outcomes.
Our study had some limitations. Firstly, this was a retro-
spective study, and our autoantibody panel comprised only 
six autoantibodies. A few recent studies have identified ad-
ditional autoantibodies, including anti-myelin oligodendro-
cyte glycoprotein (anti-MOG) antibody. Future studies with 
a more-extensive autoantibody panel would therefore be help-
ful.14,34,35 Secondly, due to the small cohort and the retrospec-
tive design of this observational study, the effectiveness of 
second-line, third-line, and maintenance immunotherapies 
could not be analyzed precisely. Further prospective studies 
of these advanced treatments are warranted. Finally, some pa-
tients diagnosed with possible seronegative AIE may have 
been misdiagnosed as autoimmune-mediated encephalitis. 
Nevertheless, it is important to note that these patients showed 
phenotypes similar to the seropositive and seronegative-prob-
able AIE patients when careful exclusion of additional diag-
noses was performed. Furthermore, the early initiation of pri-
mary immunotherapies resulted in significant improvements 
in the treatment course of AIE, and few severe side effects have 
been reported.36 Therefore, hesitation in initiating immuno-
therapies in these patients must be avoided.
In conclusion, this study found that despite slight differ-
ences, the clinical characteristics of the included patients di-
agnosed with AIE were similar regardless of their serologi-
cal status, with favorable treatment outcomes after initiating 
immunomodulatory agents. Moreover, the present findings 
indicate that treatment outcomes in patients diagnosed with 
seronegative AIE are significantly associated with the early 
initiation of primary immunotherapies, as well as the precise 
identification of disease severity after first-line treatment, thus 
suggesting autoimmune etiologies similar to those of sero-
positive AIE.
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